A new approach to targeted immunotherapy developed by researchers from Ludwig Center, the Lustgarten laboratory, and Bloomberg ~ Kimmel Institute for Cancer Immunotherapy at Johns Hopkins Kimmel Cancer Center uses new antibodies against genetically modified proteins to target cancers.
The researchers focused their immunotherapy approach on alterations in the common cancer-related p53 tumor suppressor gene, the RAS tumor promoter oncogene, or T cell receptor genes. They also tested the therapy on cancer cells. in the laboratory and on animal tumor models. Their findings are reported in three related studies published on March 1 in Scientific immunology, Science and Scientific translational medicine.
Two of the three research studies – led by Jacqueline Douglass, MD, Ph.D. candidate for the Johns Hopkins University School of Medicine and Emily Han-Chung Hsiue, MD, Ph.D., postdoctoral fellow at Johns Hopkins – reporting on a precision medicine immunotherapy approach that specifically kills cancer cells by targeting fragments of mutant proteins presented as antigens on the surface of cancer cells.
Although common to all types of cancer, p53 mutations have not been successfully targeted …
Read Additional From Source
Copyright @ www.eurekalert.org
News Highlights Science
- According to the source Development of an immunotherapy approach targeted on a mutant gene
- Check all news and articles from the Science news information updates.